REGISTERED NUMBER: 06348778 (England and Wales)

Unaudited Financial Statements

for the Year Ended 31 March 2022

<u>for</u>

Ilex Health Products Ltd

Contents of the Financial Statements for the year ended 31 March 2022

	Page
Company Information	1
Balance Sheet	2 to 3
Notes to the Financial Statements	4 to 7

Ilex Health Products Ltd

Company Information for the year ended 31 March 2022

DIRECTORS: Mr A J Nolan

Mr W J Nolan Mr V Smears Mrs B Smears Mrs K A Nolan Mrs M A Nolan

SECRETARY: Mrs B Smears

REGISTERED OFFICE: Unit 2, Brookfield

Duncan Close Moulton Park Northampton Northamptonshire

NN3 6WL

REGISTERED NUMBER: 06348778 (England and Wales)

ACCOUNTANTS: Clifford Roberts

Chartered Accountants

Pacioli House 9 Brookfield Duncan Close Northampton Northamptonshire

NN3 6WL

llex Health Products Ltd (Registered number: 06348778)

Balance Sheet 31 March 2022

		2022		2021	
	Notes	£	£	£	£
FIXED ASSETS					
Intangible assets	4		-		-
Tangible assets	5		-		-
Investments	6		59		59
			59		59
CURRENT ASSETS					
Stocks		17,801		17,046	
Debtors	7	208,674		231,421	
Cash at bank and in hand		82,994_		<u>66,806</u>	
		309,469		315,273	
CREDITORS					
Amounts falling due within one year	8	<u>61,195</u>		65,020	
NET CURRENT ASSETS			248,274		_250,253
TOTAL ASSETS LESS CURRENT					
LIABILITIES			248,333		250,312
CARITAL AND DECERVES					
CAPITAL AND RESERVES	10		2		2
Called up share capital	10		2		250.310
Retained earnings SHAREHOLDERS' FUNDS			248,331		250,310
SHAKEHULDEKS FUNDS			<u>248,333</u>		<u>250,312</u>

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2022.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2022 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Ilex Health Products Ltd (Registered number: 06348778)

Balance Sheet - continued 31 March 2022

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 20 September 2022 and were signed on its behalf by:

Mr V Smears - Director

Mr A J Nolan - Director

llex Health Products Ltd (Registered number: 06348778)

Notes to the Financial Statements for the year ended 31 March 2022

1. STATUTORY INFORMATION

Ilex Health Products Ltd is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The financial statements are presented in Sterling (£) and cover the period to 31st March each year.

Preparation of consolidated financial statements

The financial statements contain information about Ilex Health Products Ltd as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under Section 399(2A) of the Companies Act 2006 from the requirements to prepare consolidated financial statements.

Related party exemption

The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

Turnover

Turnover is measured at the fair value of consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. Turnover is recognised on the shipment of the product being sold after an order is placed by a customer.

Intangible assets

Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Patents and licences have been amortised over their estimated useful life of 3 years.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Computer equipment - 25% on cost

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Ilex Health Products Ltd (Registered number: 06348778)

Notes to the Financial Statements - continued for the year ended 31 March 2022

2. ACCOUNTING POLICIES - continued

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases, the receivables are stated at cost less impairment losses for bad and doubtful debts.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method unless the effect of discounting would be immaterial, in which case they are stated at cost.

Interest bearing borrowings

Interest bearing borrowings are recognised initially at fair value less attributable transaction costs. Subsequent to initial recognition, interest bearing borrowings are stated at amortised cost with any difference between the amount initially recognised and redemption value being recognised in the statement of comprehensive income over the period of the borrowings, together with any interest and fees payable, using the effective interest method.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 8 (2021 - 8).

llex Health Products Ltd (Registered number: 06348778)

Notes to the Financial Statements - continued for the year ended 31 March 2022

4.	INTANGIBLE FIXED ASSETS		
			Patents and licences £
	COST At 1 April 2021 and 31 March 2022 AMORTISATION		75,486
	At 1 April 2021 and 31 March 2022 NET BOOK VALUE		_75,486
	At 31 March 2022 At 31 March 2021		
5.	TANGIBLE FIXED ASSETS		Computer equipment £
	COST At 1 April 2021 and 31 March 2022 DEPRECIATION		23,790
	At 1 April 2021 and 31 March 2022 NET BOOK VALUE At 31 March 2022 At 31 March 2021		23,790
6.	FIXED ASSET INVESTMENTS		
			Other investments £
	COST At 1 April 2021 and 31 March 2022 NET BOOK VALUE		59
	At 31 March 2022 At 31 March 2021		<u>59</u> 59
7.	DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR	2022	2021
	Trada debtera	£	£
	Trade debtors Amounts owed by group undertakings Other debtors	23,132 175,488 10,054 208,674	18,373 202,982 10,066 231,421

Ilex Health Products Ltd (Registered number: 06348778)

Notes to the Financial Statements - continued for the year ended 31 March 2022

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2022	2021
	£	£
Trade creditors	12,857	6,209
Taxation and social security	41,584	53,396
Other creditors	6,754	5,415
	61,195	65,020

2022

2021

9. FINANCIAL INSTRUMENTS

The company has some exposure to foreign currency, credit, liquidity and cash flow interest rate risks, These risks are limited by the company's financial management policies and practices described below.

Foreign currency risk

The company maintains both a euro account and a dollar account, so that the timing of any financial currency exchanges can be monitored and undertaken at an opportune time ensuring foreign currency risk is mitigated as far as practical.

Credit risk

The company's exposure and it's customers credit worthiness is continually monitored so that any potential problems are detected at an early stage. The majority of the company's sales receipts are received at order which vastly reduces credit risk.

Liquidity risk

The directors have ultimate responsibility for liquidity risk management in maintaining adequate reserves and banking facilities. This is less of an issue due to immediate customer receipts than it could potentially have been.

Market risk

There is a market risk associated with the fluctuation in demand for the products and services provided. Most of this is mitigated by monitoring the markets and acting accordingly.

The company holds no derivative financial instruments at the year end.

10. CALLED UP SHARE CAPITAL

Allotted, issu	ued and fully paid:			
Number:	Class:	Nominal	2022	2021
		value:	£	£
2	Ordinary	£1	2	2

11. RELATED PARTY DISCLOSURES

During the year the company has traded with related parties, during the costs including rent, insurances and other costs were charged totalling £75,220. The balance outstanding at the year end was £6,000.

12. ULTIMATE CONTROLLING PARTY

The ultimate parent company and controlling party is Brookfield VTW Limited, a company registered in England and registered office being Unit 2, Brookfield, Duncan Close, Moulton Park, Northampton, NN3 6WL.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.